5

抓

ī

M

13

- 1. A method of treating memory disorders in individuals in need thereof, the method comprising administering to the individual an effective amount of a nicotine antagonist.
- 2. The method of claim 1 wherein the nicotine antagonist is mecamylamine, a mecamylamine analog, or a mecamylamine stereoisomer.
 - 3. The method of claim 2, wherein the effective amount of the nicotine antagonist is .005 1.00 mg/kg/day.

4. The method of claim 1 in which the memory disorder is brought on by therapy on ventional neuroleptic drugs. check the spec.

- 5. The method of claim 1 additionally comprising administration of an atypical neuroleptic drug.
- 6. A method of treating learning disorders in individuals in need thereof, the method comprising administering to the individual an effective amount of a nicotine antagonist.
- 7. The method of claim 6, wherein the nicotine antagonist is mecamylamine, a mecamylamine analog, or a mecamylamine stereoisomer.
- 8. The method of claim 7, wherein the effective amount of the nicotine antagonist is 0.005 1.00 mg/kg/day.
- 9. A method of treating age-related cognitive disorders in an individual in need thereof, the method comprising administering to the individual an effective amount of a nicotine antagonist.
- 10. The method of claim 9, wherein the nicotine antagonist is mecamylamine, a mecamylamine analog, or a mecamylamine stereoisomer.
- 11. The method of claim 9, wherein the effective amount of the nicotine antagonist is 0.005 1.00 mg/kg/day.
- 12. The method of claim 9 in which the cognitive disorder is caused or exacerbated by therapy conventional neuroloptic drugs.
- 13. The method of claim 9 additionally comprising administering an atypical neuroleptic drug.
- 14. A method of treating cognitive disorders in an individual in need thereof, the method comprising administering to the individual an effective amount of a partial nicotine agonist.

30